Abstract The need for novel therapeutics against Plasmodium falciparum is urgent due to recent emergence of multi-drug resistant malaria parasites. Since fatty acids are essential for both the liver and blood stages of the malarial parasite, targeting fatty acid biosynthesis is a promising strategy for combatting P. falciparum. We present a combined computational and experimental study to identify novel inhibitors of enoyl-acyl carrier protein reductase (PfENR) in the fatty acid biosynthesis pathway. A smallmolecule database from ChemBridge was docked into three distinct PfENR crystal structures that provide multiple receptor conformations. Two different docking algorithms were used to generate a consensus score in order to rank possible small molecule hits. Our studies led to the identification of five low-micromolar pyrimidine dione inhibitors of PfENR.
Introduction
Malaria, caused by eukaryotic protists of the genus Plasmodium, is currently one of the most deadly infectious diseases [1] . Although there are four different species of Plasmodium known to infect humans (Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae), the most life threatening cases are caused by P. falciparum [2] . Recently, malaria has become resistant to current treatments [3] including chloroquine, sulfadoxine/pyrimethamine, and artemisinin [4] [5] [6] . As a result, the need for new antimalarial treatments is urgent.
Fatty acid synthase (FAS) is responsible for the biosynthesis of fatty acids (FAs) and is essential for the survival of P. falciparum in both the liver and blood stages [7] . It was initially believed that the malaria parasite relied exclusively on exogenous fatty acids obtained from the infected organism [8, 9] . This hypothesis was later refuted after the discovery of FAS machinery in the apicoplast, a non-photosynthetic organelle in the malarial parasite [10, 11] . Recently, the strategy of targeting P. falciparum FAS in the asexual blood stage has been heavily debated. Yu et al. [12] demonstrated that knockouts of various FAS components in P. falciparum and rodent parasite Plasmodium berghei do not inhibit blood-stage growth. While exogenous FAs are sufficient for membrane biogenesis in the blood stage [13] , recent studies revealed that de novo biosynthesis is exclusively required in the liver stage of the malarial life cycle [12, 14] . Few antimalarial drugs, including atovaquone, primaquine, and anti-folates, are effective against both the blood-and liver-stage parasites. Therefore targeting the FAS in the liver stage could serve as a valuable target for future prophylactic drugs [15, 16] .
Since several antibiotics, including diazaborine [17] , triclosan [18] , thiolactomycin [19] [20] [21] , and isoniazid [22, 23] , have been used to target the FA pathway in other pathogens, other groups have similarly pursued FAS in P. falciparum [12, [24] [25] [26] [27] . P. falciparum segmented type II fatty acid synthase enzymes are structurally different from the functionally equivalent human type I FAS megasynthase, making FAS an promising target to combat malaria [28] . The human type I FAS is a single, multidomain protein, whereas P. falciparum contains a type II FAS comprised of discrete enzymes encoded by separate genes. Thus, antimalarial drugs targeting enzymes in the P. falciparum FAS would potentially be less toxic for humans due to the structural difference between the type II FAS in P. falciparum and type I FAS.
One possible strategy for disrupting FAS is to target the enoyl-acyl carrier protein (ACP) reductase (ENR, also frequently referred to as FabI), the rate-limiting enzyme in FA biosynthesis and the target of all known bacterial FAS inhibitors [18] . ENR is responsible for the reduction of trans-2-acyl-ACP to acyl-ACP (Fig. 1) [29, 30] using NADH as a cofactor. Isoniazid, an FDA-approved drug for the treatment for Mycobacterium tuberculosis targeting ENR [22] , has been applied towards antimalarial ENR drug-discovery projects [12, [24] [25] [26] , supporting this approach. Other studies have also focused on these targets [31] .
Triclosan (TCL), a trichlorinated biphenyl ether (Fig. 2 , compound 1), was discovered as an inhibitor of Escherichia coli ENR [18] , and was later found to similarly target PfENR [12, [24] [25] [26] . Structural studies suggest that TCL binds PfENR at its acyl substrate-binding pocket [32] , where it forms a stable ternary complex with the protein and the oxidized cofactor (NAD ? ). Additionally, several TCL-analogues have demonstrated inhibition of PfENR, and co-crystal structures of PfENR with these analogues (Fig. 2, compounds 2-6 ) display similar binding conformations to the TCL-PfENR complex [33] . The various pocket poses with TCL and its analogues bound to the acyl substrate-binding pocket offer an excellent starting point for structure-based drug design studies in PfENR.
Structure-based drug design is a powerful approach in drug discovery when the atomic structure of the target protein is known [34] . Comprehensive computational and experimental studies elucidating both the structural [28, 33] and dynamic [35] [36] [37] [38] [39] nature of PfENR have been performed, with applications to drug discovery [40] [41] [42] [43] . With the advancement in computational and experimental technology, we can rationally and efficiently screen for novel drugs with a higher hit rate than the traditional and more expensive high-throughput library screens. In this study, we present a joint computational and experimental study that employs multiple PfENR crystal structures to account for receptor flexibility in the in silico screening process. Additionally a consensus of two independent docking programs, AutoDock Vina and Glide, was used to refine the experimental screens and reduce false positives. This protocol allowed us to identify new low-micromolar PfENR inhibitors that are reported for the first time from the ChemBridge small molecule repository.
Materials and methods

Preparation of ENR crystal structures
Systems based on three different crystal structures were prepared for docking simulations: PDB entries 1UH5 [28] , 3LSY [33] , and 3LT0 [33] . The resolution of the structures is 2.2, 2.9 and 2.0 Å , respectively. These crystal structures were chosen based on scoring of known inhibitors after docking into 17 PfENR crystal structures (unpublished data). 1UH5 contains triclosan (TCL; Fig. 2 , compound 1) and 3LSY and 3LT0 contain triclosan variants FT0 and FT1, respectively (Fig. 2, compounds 2 and 3 ). All three structures contained an NAD ? cofactor. The missing substrate-binding loop residues (325-366) were built into all three crystal structures using Swiss model server [44] in order to have a complete protein model for MD simulations. For the AutoDock Vina screens, pdb2pqr [45, 46] was used to add hydrogen atoms to the first subunits of the crystal structure receptors. Ligands and cofactors were removed from the AutoDock Vina receptor files. Removal of the cofactor allowed us to probe binding to the cofactor binding site in addition to the substrate binding site. The AutoDock script [47] prepare_receptor4.py was used to prepare the final receptor pdbqt files. For the Glide screens, the receptors were prepared using the tools provided in the Maestro Protein Preparation Wizard [48] and the Glide Receptor Grid Generation [49, 50] . Ligands 1 (TCL), 2, (FT0), and 3 (FT1) were removed from the Glide receptor grid files, while the cofactors were left in the binding site.
Docking of known ENR inhibitors
We evaluated the ability of both docking programs to dock triclosan (1) and five of its analogues (2-6) into the three crystal structures [28, 33] (Fig. 3) . The known inhibitors used in this analysis (compounds 1-6) are shown in A Three established PfENR structures were chosen for docking (PDB: 1UH5, 3LSY, 3LT0). B The docking protocols were evaluated for their ability to dock known inhibitors of PfENR. Inhibitors and cofactors were removed from the AutoDock Vina receptor files, while only inhibitors were removed from the Glide receptor grid files. The inhibitors were re-docked into these prepared structures and evaluated for their ability to dock known inhibitors by calculating the RMSD. C After establishing a validated docking program, 171,791 compounds from the ChemBridge EXPRESS-Pick compound collection were docked into the prepared ENR structures and a consensus in silico small molecule hit set was generated for in vitro testing ionization states, as well as tautomers for compounds 1-6. The AutoDock script [47] prepare_ligand4.py was used to prepare the inhibitor pdbqt files for the AutoDock Vina screens. Due to the lack of the cofactor, the AutoDock Vina results were only analyzed in terms of deviation from known bound pose.
To evaluate the ability of the docking programs to rank binders better than non-binders, a ROC-AUC (Receiver Operating Characteristics-Area Under the Curve) analysis [51] was performed on the three crystal structures. For this, we used Glide to dock the six known inhibitors (compounds 1-6) and the Schrödinger decoy library (1,000 compounds with average molecular mass of *400 Daltons [49, 50] ). All compounds in the decoy set were assumed to be inactive. All 1,006 compounds were docked into all three receptor structures. The compounds were ranked by their Glide XP docking scores, and AUC values were calculated from the ROC analysis.
Virtual screen of ChemBridge database
The virtual screen was performed using the ChemBridge EXPRESS-Pick compound collection (September 2012 update, http://www.chembridge.com/screening_libraries/). Compounds not available in sufficient quantities for reordering were removed from the dataset. The ChemBridge EXPRESS-Pick Collection contained 448,532 compounds which were selected by ChemBridge using novelty, diversity, drug-like properties, and chemical structure analyses as criteria. It covers a broad area of chemical space, offering diverse classes of compounds with analogues to support initial SAR work. The OpenEye filter program was used to remove undesirable compounds, with particular focus on removal of unwanted functional groups, reactive compounds and unwanted protecting group compounds. Filter default settings were used. Deviations from the default values included: compound molecular weight between 250 and 460 Da, removal of salts, duplicate structures and compounds with 3 or more (out of 4) Lipinski violations [52] , removal of known aggregators (retention of ''OE predicted aggregators''), predicted solubility cut-off ''poorly'' (or worse), and \10 rotatable bonds. As a result, 101,692 small molecules were obtained after applying these filters. Ligands were then prepared using LigPrep, adding missing hydrogen atoms, generating all possible ionization states, and tautomers. The final set used for virtual screening contained 171,791 compounds. Docking simulations were performed with both AutoDock Vina [53] as well as Glide [49, 50, 54] . The AutoDock script [47] prepare_ligand4.py was used to prepare the ligand pdbqt files for the AutoDock Vina screens. Vina docking was performed into empty active sites, i.e. ligands and cofactors were removed from the AutoDock Vina receptor files. A docking grid of size 18.0 Å 9 18.0 Å 9 18.0 Å , centered on the position of the crystallographic ligand in the binding site, was used for docking. For Glide docking, the ligands were prepared using LigPrep. Glide docking was performed into cofactor-occupied active sites, i.e. only ligands had been removed from the Glide receptor files. The different docking protocols correspond to strategies of finding inhibitors that occupy either the crotonyl-CoA substrate binding site (in the case of Glide) or also the NAD ? cofactor binding site (in the case of AutoDock Vina). These different strategies were pursued to improve the likelihood of finding novel ENR inhibitors. The individual AutoDock Vina and Glide rankings were combined to form a consensus list of compounds that scored well with both methods, a method that has been reported previously to be successful in virtual screening [55] .
Analogue ligand-based search from lead compound Based on the experimental hit (Fig. 2, compound 9) , a ligand-based search of the ChemBridge database was performed with the goal of testing similar compounds for inhibition of PfENR. The sdf file connected to ChemBridge ID 7056672 (compound 9) was downloaded. We used Canvas [56, 57] for a substructure-based search on the key pyrimidine dione pharmacophore of 9. The resulting 2,545 compounds were ranked by drug-like properties. Fifteen compounds from that list were chosen for ordering and testing.
PfENR expression and purification
PfENR was subcloned into a pET28a plasmid and transformed into E. coli BL21 cells, which has been previously described [58] . Cells were grown at 37°C to a final OD of 1.0 without the addition of IPTG in terrific broth medium containing 100 mg/L kanamycin sulfate. The pellet was resuspended in lysis buffer (20 mM Tris/HCl buffer with 150 mM NaCl, pH 7.4), and supplemented with 0.1 mg/ mL lysozyme (Worthington Biochemical Corp), 5 lg/mL DNAse I (Sigma), and 5 lg/mL RNAse (Worthington Biochemical Corp.). The supernatant was batch-bound with Ni-NTA resin (Qiagen) for an hour at 4°C and washed with 20 mM Tris/HCl with 150 mM NaCl, pH 7.4. The protein was eluted from the resin using a step gradient of lysis buffer supplemented with 60-300 mM imidazole. PfENR was further purified via size exclusion chromatography using a HiPrep Sephacryl 16/60 S-200 (GE Healthcare) equilibrated with lysis buffer. PfENR was concentrated with a 10-kDa Amicon spin filter (Milipore) and stored at -20°C in 40 % glycerol, 20 mM Tris/HCl buffer with 150 mM NaCl.
Validation of the in silico compounds by continuous assay
One-hundred and twenty small molecules identified as hits by our in silico analysis were purchased through ChemBridge and tested for PfENR inhibition. All ChemBridge compounds had [90 % purity as verified by spectra analysis. The final 100 lL reaction volume contained 50 lM NAD ? , 20 mM Tris/HCl buffer, 150 mM NaCl (pH 7.4), 200 lM crotonyl-CoA, 100 lM NADH, and 0.05 lM ENR. Each inhibitor was evaluated for potency at a final concentration of 50 lM and took 5 % of the reaction volume after dissolving in DMSO. PfENR was preincubated with NAD
? and inhibitor at 27°C for 45 min and initiated with a final concentration of 200 lM crotonylCoA and 100 lM NADH cocktail following this preincubation period. PfENR inhibition was observed at 27°C by monitoring the consumption of NADH via change in absorbance at 340 nm (e NADH = 6.22 mM -1 cm -1 ) (Perkin Elmer HTS 7000 Plus Bio Assay Reader) and repeated in triplicate.
PfENR inhibition assay
To evaluate the IC 50 of lead compounds 7-13, NADH consumption was measured at varying concentrations in triplicate. The final 100 lL reaction volume contained 50 lM NAD ? , 20 mM Tris/HCl buffer, 150 mM NaCl (pH 7.4), 200 lM crotonyl-CoA, 100 lM NADH, and 0.05 lM ENR. ENR was preincubated at 27°C for 45 min with a final concentration of 50 lM NAD ? , 20 mM Tris/HCl buffer, 150 mM NaCl (pH 7.4), and 0.9-75 lM inhibitor. Following this preincubation period, the reaction was initiated with a final concentration of 200 lM crotonyl-CoA and 100 lM NADH.
Results and discussion
Docking of known ENR inhibitors: Glide yields high AUC values in ROC analysis
The protocol for the docking of known inhibitors mirrored the protocol of the virtual screen. Glide receptors contained cofactors while AutoDock Vina receptors had both the ligands and cofactors removed (Fig. 3) . Since the AutoDock Vina receptors have been prepared without the cofactor present, it is not expected to see good agreement between docked and known poses or even enrichment with respect to a set of decoys. Thus no ROC-AUC analysis was performed using AutoDock Vina. As expected, docked poses are found scattered all over the active site cavity because no cofactor is present to restrain the docked pose to the substrate binding active site. However, the crystallographic TCL pose is recovered by Vina docking despite the absence of the cofactor. Figure 4A shows an overlay of one of the TCL docked poses with its crystallographic position with an RMSD of 0.87 Å and supports our AutoDock Vina methodology. A much more detailed analysis of the Glide docking results was possible since its receptors contained the crystallographic cofactor coordinates. Glide is thus expected to rank the known inhibitors high compared to the decoys. A ROC-AUC analysis yielded AUCs of 0.90, 0.92 and 0.92 for docking of 1,006 compounds (six known inhibitors and 1,000 decoys) into 1UH5, 3LSY and 3LT0 respectively. As a representative example, Fig. 4B shows the ROC plot for 3LSY. These results suggest that Glide can differentiate actives from inactives in the presence of the cofactor.
In silico screen and compound selection Three crystal structures of PfENR bound to triclosan (1) or triclosan variants (2-6) were used as receptors for the relaxed complex scheme docking protocol using a combination of AutoDock Vina and Glide. The ChemBridge Database was used as screening library. Both the AutoDock Vina and Glide XP docking results were ranked individually according to the predicted docking score. A consensus list of compounds containing high docking scores was generated from the Vina and Glide lists. The top 90 compounds from this list, as well as the top 15 scoring compounds from the individual AutoDock Vina and Glide lists, respectively, were selected for experimental investigation.
Confirmation of PfENR inhibition via enzymatic assays
We used a continuous assay to evaluate the inhibition of the 120 compounds recommended by our in silico studies. Without inhibitor, consumption of NADH was observed at 340 nm and a change in absorbance is observed and normalized to 1 (bar labeled DMSO in Fig. 5 ). As a negative control, we tested cerulenin (CR), a commercially available inhibitor of b-ketoacyl-acyl-carrier protein synthase (KS-ACP-II) (Fig. 5) [59] . No inhibition of PfENR was observed, similar to the results obtained in the presence of DMSO alone. As a positive control, we tested TCL (1), a known PfENR inhibitor, and observed no change in NADH consumption indicative of ENR inhibition (Fig. 5) [60] . The inhibition of 120 compounds (ChemBridge) from the in silico screen at a final concentration of 50 lM (data not reported) were tested using this continuous assay. A change in absorbance at 340 nm below 30 % inhibition was used as a criterion for the next set of inhibitor leads. The top 22 compounds from the 120 small molecule set were further evaluated for inhibition using the continuous assay. Most of the 22 compounds, except compounds 7-9, exhibited a change in absorbance above 1 relative to the negative control (DMSO and CR) at a final concentration of 50 lM (Fig. 5) . We hypothesize that many of these compounds precipitate under the reaction conditions resulting in a higher absorbance at 340 nm. Since TCL inhibits PfENR in the picomolar to nanomolar range [33, 61] , we decided to test inhibitor concentrations that are in the mid-micromolar range for PfENR.
Compounds 7-9 were further evaluated for their ability to inhibit PfENR by examining their IC 50 . Due to solubility issues, an IC 50 curve was not attained for compounds 7-8. Soluble compound 9 was observed to have an average IC 50 of 4.6 lM (Fig. 6 ). IC 50 measurements were not attempted for all other compounds due to lack of sufficient inhibition at 50 lM.
To further evaluate the chemical moieties important for PfENR inhibition, analogues of 9 (F) were tested (Fig. 5B) . The continuous assay was used to evaluate the relative inhibition for each analogue. Compounds 10-13 exhibited minimal change in absorbance at 340 nm indicative of inhibition of PfENR. A change in absorbance at 340 nm below 0.7 was used as a criterion to further determine the IC 50 . The average IC 50 was calculated for the 4 analogues (Fig. 6) , compounds 10-13, and was 7.8, 8.8, 14.3 and 2.1 lM, respectively.
It is also interesting to note that ChemBridge compound 9 (F) only scored well within the AutoDock Vina protocol suggesting that it may at least in part occupy the cofactor binding site. Since different docking protocols were used for AutoDock Vina (no cofactor present during docking) and Glide (cofactor present during docking) this may highlight the value of targeting the cofactor part of the active site as opposed to solely focusing on competitive substrate binding site inhibitors.
Conclusion
A number of leads for PfENR inhibitors have been identified in a relaxed complex scheme virtual screen of the active site. The most potent leads, 9-13, were all pyrimidine diones with IC 50 values in the *1-15 lM range. All leads obey Lipinski's rule of five, making them interesting drug-like chemical starting points. These results highlight the potential of combined computational and biochemical work to discover novel binding scaffolds. How these compounds bind to PfENR remains to be determined. Based on their high scoring performance in the AutoDock Vina docking protocol we speculate that 9-13 partly occupy the cofactor binding site, thus interacting with cofactor binding residues. Supplemental Figure 1 shows the best-predicted docking pose for compounds 9-13, obtained when the compound was docked into the 1UH5 structure. Further lead optimization will focus on elucidating the binding interactions by X-ray crystallography and development of nanomolar pyrimidine dione inhibitors. As a result of our current work, a drug discovery effort has been launched that may serve as a critical next step for structure-based drug design and optimization. 
